Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.
| Drug | Target | Relationship | GBM | LUAD | SCLC | LUSC | OAC | OSCC | PDAC | Reposition | #cancers |
|---|---|---|---|---|---|---|---|---|---|---|---|
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | PIK3CB | Direct | 3 | ||||||||
| biopsy, biospecimen collection, computed tomography, copanlisib, magnetic resonance imaging | PIK3CB | Direct | 1 | ||||||||
| biopsy, biospecimen collection, copanlisib, radiologic examination | PIK3CB | Direct | 1 | ||||||||
| afatinib | EGFR | SSL via EGFR | yes | 2 | |||||||
| dacomitinib | EGFR | SSL via EGFR | yes | 2 | |||||||
| erlotinib | EGFR | SSL via EGFR | yes | 2 | |||||||
| gefitinib | EGFR | SSL via EGFR | yes | 2 | |||||||
| lazertinib and amivantamab | EGFR | SSL via EGFR | 1 | ||||||||
| osimertinib | EGFR | SSL via EGFR | yes | 1 | |||||||
| neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab | DDR2 | SSL via DDR2 | 4 | ||||||||
| regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) | DDR2 | SSL via DDR2 | 4 | ||||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | EPHB4 | SSL via EPHB4 | 3 | ||||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | ERBB2 | SSL via ERBB2 | 3 | ||||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | MAP2K2 | SSL via MAP2K2 | 3 | ||||||||
| adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib | PIK3CA | SSL via PIK3CA | 3 | ||||||||
| afatinib | ERBB2 | SSL via ERBB2 | yes | 3 | |||||||
| mrtx849, pembrolizumab, cetuximab, afatinib | ERBB2 | SSL via ERBB2 | 3 | ||||||||
| trastuzumab emtansine | ERBB2 | SSL via ERBB2 | yes | 3 | |||||||
| tucatinib | ERBB2 | SSL via ERBB2 | yes | 3 | |||||||
| alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel | ERBB2 | SSL via ERBB2 | 2 | ||||||||
| alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel | MAP2K2 | SSL via MAP2K2 | 2 | ||||||||
| bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment | EPHB4 | SSL via EPHB4 | 2 | ||||||||
| binimetinib, biopsy, biospecimen collection, bone scan, computed tomography, magnetic resonance imaging, palbociclib | MAP2K2 | SSL via MAP2K2 | 2 | ||||||||
| cft1946, trametinib, cetuximab | MAP2K2 | SSL via MAP2K2 | 2 | ||||||||
| eft226, sotorasib, fulvestrant, abemaciclib, trastuzumab | ERBB2 | SSL via ERBB2 | 2 | ||||||||
| entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib | ERBB2 | SSL via ERBB2 | 2 | ||||||||
| jab-3312, binimetinib, pembrolizumab, sotorasib, osimertinib | MAP2K2 | SSL via MAP2K2 | 2 | ||||||||
| lapatinib | ERBB2 | SSL via ERBB2 | yes | 2 | |||||||
| radiotherapy targeted to the primary lesion, radiotherapy targeted to the metastatic lesions, anti-pd-1 monoclonal antibody, trastuzumab, chemotherapy, r0 total/subtotal gastrectomy with d2 lymphadenectomy, metastasectomy, local ablative therapies | ERBB2 | SSL via ERBB2 | 2 | ||||||||
| regorafenib | DDR2 | SSL via DDR2 | yes | 2 | |||||||
| regorafenib, laboratory biomarker analysis | DDR2 | SSL via DDR2 | 2 | ||||||||
| selumetinib, medi4736, tremelimumab | MAP2K2 | SSL via MAP2K2 | 2 | ||||||||
| trastuzumab | ERBB2 | SSL via ERBB2 | yes | 2 | |||||||
| trastuzumab, abt-806, bemarituzumab, ramucirumab, nivolumab, standard cytotherapy | ERBB2 | SSL via ERBB2 | 2 | ||||||||
| trastuzumab, tipifarnib | ERBB2 | SSL via ERBB2 | 2 | ||||||||
| 2b3-101, trastuzumab, 2b3-101 60 mg/m2 every 4 weeks, 2b3-101 50 mg/m2 every 3 weeks | ERBB2 | SSL via ERBB2 | 1 | ||||||||
| 5-fu, leucovorin, docetaxel, oxaliplatin (flot), trastuzumab, post-operative treatment trastuzumab mono therapy | ERBB2 | SSL via ERBB2 | 1 | ||||||||
| afatinib, biopsy, biospecimen collection, computed tomography, echocardiography, magnetic resonance imaging, radionuclide imaging | ERBB2 | SSL via ERBB2 | 1 | ||||||||
| afatinib, dasatinib, palbociclib, everolimus, olaparib | EPHB4 | SSL via EPHB4 | 1 | ||||||||
| afatinib, dasatinib, palbociclib, everolimus, olaparib | ERBB2 | SSL via ERBB2 | 1 | ||||||||
| afatinib, docetaxel, radiation therapy | ERBB2 | SSL via ERBB2 | 1 | ||||||||
| afatinib, gefitinib | ERBB2 | SSL via ERBB2 | 1 | ||||||||
| afatinib, irinotecan | ERBB2 | SSL via ERBB2 | 1 | ||||||||
| akt inhibitor mk2206, fluorouracil, oxaliplatin, selumetinib | MAP2K2 | SSL via MAP2K2 | 1 | ||||||||
| alpelisib, everolimus, exemestane | PIK3CA | SSL via PIK3CA | 1 | ||||||||
| bevacizumab, dasatinib, placebo | EPHB4 | SSL via EPHB4 | 1 | ||||||||
| binimetinib | MAP2K2 | SSL via MAP2K2 | yes | 1 | |||||||
| binimetinib, hydroxychloroquine | MAP2K2 | SSL via MAP2K2 | 1 | ||||||||
| biopsy, biospecimen collection, computed tomography, copanlisib, magnetic resonance imaging | PIK3CA | SSL via PIK3CA | 1 | ||||||||
| biopsy, biospecimen collection, copanlisib, radiologic examination | PIK3CA | SSL via PIK3CA | 1 | ||||||||
| biopsy, biospecimen collection, echocardiography, pertuzumab, radiologic examination, trastuzumab | ERBB2 | SSL via ERBB2 | 1 | ||||||||
| bosutinib | MAP2K2 | SSL via MAP2K2 | 1 | ||||||||
| capecitabine, medi4736 (durvalumab), trastuzumab, rucaparib, ramucirumab | ERBB2 | SSL via ERBB2 | 1 | ||||||||
| carboplatin, laboratory biomarker analysis, paclitaxel, quality-of-life assessment, radiation therapy, therapeutic conventional surgery, trastuzumab | ERBB2 | SSL via ERBB2 | 1 | ||||||||
| cetuximab, trastuzumab | ERBB2 | SSL via ERBB2 | 1 | ||||||||
| cisplatin, 5-fluorouracil or capecitabine, trastuzumab, pertuzumab, gastrectomy | ERBB2 | SSL via ERBB2 | 1 | ||||||||
| dabrafenib, trametinib | MAP2K2 | SSL via MAP2K2 | 1 | ||||||||
| dabrafenib, trametinib, carboplatin, vincristine | MAP2K2 | SSL via MAP2K2 | 1 | ||||||||
| dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride | EPHB4 | SSL via EPHB4 | 1 | ||||||||
| dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method | EPHB4 | SSL via EPHB4 | 1 | ||||||||
| dasatinib, laboratory biomarker analysis, physiologic testing | EPHB4 | SSL via EPHB4 | 1 | ||||||||
| dasatinib, mfolfox6 | EPHB4 | SSL via EPHB4 | 1 | ||||||||
| dasatinib, pharmacological study | EPHB4 | SSL via EPHB4 | 1 | ||||||||
| dasatinib, temozolomide, placebo, radiation therapy | EPHB4 | SSL via EPHB4 | 1 | ||||||||
| db-1310, trastuzumab, osimertinib | ERBB2 | SSL via ERBB2 | 1 | ||||||||
| dimethyl fumarate, temozolomide, radiation therapy | KEAP1 | SSL via KEAP1 | 1 | ||||||||
| disitamab vedotin, tucatinib | ERBB2 | SSL via ERBB2 | 1 | ||||||||
| docetaxel, leucovorin, fluorouracil, cisplatin, docetaxel, cisplatin, fluorouracil, neulasta, or neupogen, docetaxel, leukvorin, flurouracil, cisplatin, trastuzumab | ERBB2 | SSL via ERBB2 | 1 | ||||||||
| docetaxel, oxaliplatin, capecitabine, trastuzumab | ERBB2 | SSL via ERBB2 | 1 | ||||||||
| erlotinib hydrochloride, selumetinib, laboratory biomarker analysis | MAP2K2 | SSL via MAP2K2 | 1 | ||||||||
| evorpacept (alx148), trastuzumab, ramucirumab, paclitaxel | ERBB2 | SSL via ERBB2 | 1 | ||||||||
| fluorouracil (5-fu), capecitabine, durvalumab, oxaliplatin, trastuzumab, trastuzumab deruxtecan, cisplatin, pembrolizumab, volrustomig, rilvegostomig | ERBB2 | SSL via ERBB2 | 1 | ||||||||
| gemcitabine, oxaliplatin, imatinib | DDR2 | SSL via DDR2 | 1 | ||||||||
| gemcitabine, ribociclib, sonidegib, trametinib, filgrastim | MAP2K2 | SSL via MAP2K2 | 1 | ||||||||
| gsk2256098, trametinib | MAP2K2 | SSL via MAP2K2 | 1 | ||||||||
| imatinib, irinotecan, carboplatin | DDR2 | SSL via DDR2 | 1 | ||||||||
| laboratory biomarker analysis, lapatinib, lapatinib ditosylate, pharmacological study, therapeutic conventional surgery | ERBB2 | SSL via ERBB2 | 1 | ||||||||
| lapatinib, chemoradiation, placebo | ERBB2 | SSL via ERBB2 | 1 | ||||||||
| lapatinib, placebo | ERBB2 | SSL via ERBB2 | 1 | ||||||||
| lapatinib, placebo, capecitabine, oxaliplatin | ERBB2 | SSL via ERBB2 | 1 | ||||||||
| lonsurf, oxaliplatin, panitumumab, bevacizumab, trastuzumab, nivolumab | ERBB2 | SSL via ERBB2 | 1 | ||||||||
| nal-iri, oxaliplatin, 5-fu, trastuzumab, pembrolizumab, nivolumab | ERBB2 | SSL via ERBB2 | 1 | ||||||||
| oxaliplatin, leucovorin, 5 fluorouracil, trastuzumab, avelumab | ERBB2 | SSL via ERBB2 | 1 | ||||||||
| palbociclib, afatinib | ERBB2 | SSL via ERBB2 | 1 | ||||||||
| pazopanib, lapatinib | ERBB2 | SSL via ERBB2 | 1 | ||||||||
| pembrolizumab, placebo, cisplatin, 5-fu, oxaliplatin, capecitabine, s-1, trastuzumab | ERBB2 | SSL via ERBB2 | 1 | ||||||||
| pembrolizumab, trastuzumab, oxaliplatin, capecitabine | ERBB2 | SSL via ERBB2 | 1 | ||||||||
| regorafenib, lomustine | DDR2 | SSL via DDR2 | 1 | ||||||||
| regorafenib, nivolumab, capeox, folfox regimen | DDR2 | SSL via DDR2 | 1 | ||||||||
| regorafenib, nivolumab, docetaxel, paclitaxel, irinotecan, trifluridine/tipracil | DDR2 | SSL via DDR2 | 1 | ||||||||
| regorafenib, temozolomide | DDR2 | SSL via DDR2 | 1 | ||||||||
| selumetinib | MAP2K2 | SSL via MAP2K2 | yes | 1 | |||||||
| temozolomide, lomustine, regorafenib, radiation, paxalisib, val-083, vt1021, troriluzole, adi-peg 20 | DDR2 | SSL via DDR2 | 1 | ||||||||
| tesevatinib | EPHB4 | SSL via EPHB4 | 1 | ||||||||
| tesevatinib | ERBB2 | SSL via ERBB2 | 1 | ||||||||
| tirelizumab, trastuzumab, docetaxel, s1, oxaliplatin | ERBB2 | SSL via ERBB2 | 1 | ||||||||
| trametinib, erlotinib | MAP2K2 | SSL via MAP2K2 | 1 | ||||||||
| trametinib, ruxolitinib | MAP2K2 | SSL via MAP2K2 | 1 | ||||||||
| trametinib, ruxolitinib, retifanlimab | MAP2K2 | SSL via MAP2K2 | 1 | ||||||||
| trametinib, vinblastine | MAP2K2 | SSL via MAP2K2 | 1 |